Prostatic Neoplasms

"Prostatic Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Tumors or cancer of the PROSTATE.

Descriptor ID	D011471
MeSH Number(s)	C04.588.945.440.770 C12.294.260.750 C12.294.565.625 C12.758.409.750
Concept/Terms	Prostatic Neoplasms Prostatic Neoplasms Prostate Neoplasms Neoplasms, Prostate Neoplasm, Prostate Prostate Neoplasm Neoplasms, Prostatic Neoplasm, Prostatic Prostatic Neoplasm Prostate Cancer Prostate Cancer Cancer, Prostate Cancers, Prostate Prostate Cancers Cancer of the Prostate Prostatic Cancer Cancer, Prostatic Cancers, Prostatic Prostatic Cancers Cancer of Prostate

Below are MeSH descriptors whose meaning is more general than "Prostatic Neoplasms".

Diseases [C]
Neoplasms [C04]
Neoplasms by Site [C04.588]
Urogenital Neoplasms [C04.588.945]
Genital Neoplasms, Male [C04.588.945.440]
Prostatic Neoplasms [C04.588.945.440.770]
Male Urogenital Diseases [C12]
Genital Diseases, Male [C12.294]
Genital Neoplasms, Male [C12.294.260]
Prostatic Neoplasms [C12.294.260.750]
Prostatic Diseases [C12.294.565]
Prostatic Neoplasms [C12.294.565.625]
Urogenital Neoplasms [C12.758]
Genital Neoplasms, Male [C12.758.409]
Prostatic Neoplasms [C12.758.409.750]

Below are MeSH descriptors whose meaning is related to "Prostatic Neoplasms".

Below are MeSH descriptors whose meaning is more specific than "Prostatic Neoplasms".

Prostatic Neoplasms
Prostatic Neoplasms, Castration-Resistant

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Prostatic Neoplasms" by people in this website by year, and whether "Prostatic Neoplasms" was a major or minor topic of these publications.

Bar chart showing 690 publications over 28 distinct years, with a maximum of 49 publications in 2012

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1997	1	0	1
1998	3	0	3
1999	1	0	1
2000	5	1	6
2001	10	0	10
2002	4	1	5
2003	9	2	11
2004	15	0	15
2005	15	1	16
2006	20	4	24
2007	20	6	26
2008	23	3	26
2009	24	1	25
2010	37	6	43
2011	39	7	46
2012	45	4	49
2013	34	2	36
2014	32	4	36
2015	41	4	45
2016	40	1	41
2017	34	3	37
2018	21	5	26
2019	27	0	27
2020	35	1	36
2021	25	0	25
2022	30	0	30
2023	31	0	31
2024	12	1	13

Below are the most recent publications written about "Prostatic Neoplasms" by people in Profiles.

Adekiya TA, Hudson T, Bakare O, Ameyaw EE, Adebayo A, Olajubutu O, Adesina SK. PSMA-targeted combination brusatol and docetaxel nanotherapeutics for the treatment of prostate cancer. Biomed Pharmacother. 2024 Aug; 177:117125.

View in: PubMed
Liou GY, C'lay-Pettis R, Kavuri S. Involvement of Reactive Oxygen Species in Prostate Cancer and Its Disparity in African Descendants. Int J Mol Sci. 2024 Jun 17; 25(12).

View in: PubMed
Elbialy A, Kappala D, Desai D, Wang P, Fadiel A, Wang SJ, Makary MS, Lenobel S, Sood A, Gong M, Dason S, Shabsigh A, Clinton S, Parwani AV, Putluri N, Shvets G, Li J, Liu X. Patient-Derived Conditionally Reprogrammed Cells in Prostate Cancer Research. Cells. 2024 Jun 08; 13(12).

View in: PubMed
Thompson CA, Sheridan P, Metwally E, Peacock Hinton S, Mullins MA, Dillon EC, Thompson M, Pettit N, Kurian AW, Pruitt SL, Lyratzopoulos G. Emergency department involvement in the diagnosis of cancer among older adults: a SEER-Medicare study. JNCI Cancer Spectr. 2024 Apr 30; 8(3).

View in: PubMed
Garraway IP, Carlsson SV, Nyame YA, Vassy JL, Chilov M, Fleming M, Frencher SK, George DJ, Kibel AS, King SA, Kittles R, Mahal BA, Pettaway CA, Rebbeck T, Rose B, Vince R, Winn RA, Yamoah K, Oh WK. Prostate Cancer Foundation Screening Guidelines for Black Men in the United States. NEJM Evid. 2024 May; 3(5):EVIDoa2300289.

View in: PubMed
Brown LK, Kanagasabai T, Li G, Celada SI, Rumph JT, Adunyah SE, Stewart LV, Chen Z. Co-targeting SKP2 and KDM5B inhibits prostate cancer progression by abrogating AKT signaling with induction of senescence and apoptosis. Prostate. 2024 Jun; 84(9):877-887.

View in: PubMed
Yeyeodu S, Hanafi D, Webb K, Laurie NA, Kimbro KS. Population-enriched innate immune variants may identify candidate gene targets at the intersection of cancer and cardio-metabolic disease. Front Endocrinol (Lausanne). 2023; 14:1286979.

View in: PubMed
Ross L, Preston MA, Lee TC, Lockhart J, Young J, Wood A, Wood R. Exploring Information Seeking Anxiety Among Localized Prostate Cancer Patients. Am J Mens Health. 2024 Mar-Apr; 18(2):15579883241240339.

View in: PubMed
Chiarelli G, Davis M, Stephens A, Cirulli GO, Finati M, Corsi NJ, Sood A, Tinsley S, Carrieri G, Briganti A, Montorsi F, Lughezzani G, Buffi N, Rogers C, Abdollah F. Comparison of patient background between a real-world North American cohort and the G?teborg-2 trial. Int J Urol. 2024 May; 31(5):562-567.

View in: PubMed
Noriega Landa E, Quaye GE, Su X, Badmos S, Holbrook KL, Polascik TJ, Adams ES, Deivasigamani S, Gao Q, Annabi MH, Habib A, Lee WY. Urinary fatty acid biomarkers for prostate cancer detection. PLoS One. 2024; 19(2):e0297615.

View in: PubMed

People

Explore

Similar Concepts

Top Journals